The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients.
We performed a population-based cohort study to assess the impact of nonwhite origin on the outcome of highly active antiretroviral therapy (HAART) for a Danish cohort of human immunodeficiency virus (HIV)-infected patients. A total of 389 whites and 135 nonwhites started receiving HAART before 1 April 2001. After 1 year of treatment, 78% of nonwhites and 76% of whites achieved a virus load of <500 HIV RNA copies/mL. No major differences were found between the 2 groups with respect to achievement of a virus load of <500 copies/mL (relative risk [RR], 0.94; 95% confidence interval [CI], 0.74-1.18), risk of clinical progression (RR, 0.63; 95% CI, 0.32-1.24), or response measured by total CD4+ cell count. One year after fulfilling Danish recommendations for initiation of HAART, 91% of nonwhites and 93% of whites had started receiving HAART. Race and ethnic origin play no major role in the outcome associated with HAART if access to health care is free.
Jensen-Fangel
Søren
S
Department of Infectious Diseases, Aarhus University Hospital, Skejby Hospital, DK-8200 Aarhus N, Denmark. fangel@dadlnet.dk
Pedersen
Lars
L
Pedersen
Court
C
Larsen
Carsten Schade
CS
Tauris
Palle
P
Møller
Axel
A
Sørensen
Henrik Toft
HT
Obel
Niels
N
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000208:ethnology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D008297:Male
D019380:Anti-HIV Agents